ArticleBMC infectious diseases2026
Development and validation of a risk nomogram model for predicting superficial fungal infections in patients with type 2 diabetes mellitus : a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo develop and validate a nomogram for the individualized prediction of superficial fungal infections (SFI) risk in patients with type 2 diabetes mellitus (T2DM).
methodsThis cross-sectional study enrolled patients with T2DM from the Affiliated Anning First People’s Hospital of Kunming University of Science and Technology between December 2023 and December 2024. Risk factors were identified using multivariable logistic regression, and a nomogram was developed subsequently for predicting SFI in T2DM patients. The model’s performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA) and clinical impact curve (CIC) in the training and validation sets.
resultsAmong 308 hospitalized T2DM patients screened by multiplex quantitative polymerase chain reaction (qPCR), 220 (71.40%) were diagnosed with SFI. Trichophyton rubrum (107 cases) was the most common pathogen, and monoinfection was the most frequent presentation (90 patients). Patients were randomly divided into a training (n = 216) and a validation cohort (n = 92) in a 7:3 ratio. Multivariable logistic regression analysis identified eight key variables: body mass index (BMI), blood glucose (Glu), hemoglobin A1c (HbA1c), urinary albumin-to-creatinine ratio (UACR), serum potassium (K+), sodium (Na+), hyperlipidemia (HLP) and hypertension (HTN). The nomogram demonstrated excellent predictive ability. The ROC analysis indicated good discrimination in the training cohort (area under the curve (AUC) = 0.966; 95% CI, 0.945–0.987) and the validation cohort (AUC = 0.931; 95% CI, 0.877–0.985). The optimal cut-point of the nomogram was 0.624 with a sensitivity of 92.3% and specificity of 86.7% (Youden’s index: 0.79). Calibration curves showed good agreement. DCA confirmed the clinical utility of the nomogram.
conclusionThis nomogram effectively predicts the risk of SFI in T2DM patients and provides an objective tool to facilitate early identification and intervention by clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.